Last reviewed · How we verify

NCT06960863

Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma

Recruiting now Last updated 7 May 2025
What this trial tests

trial testing fibroscan in Hepato Cellular Carcinoma (HCC) in 80 participants. Currently enrolling.

Timeline
26 January 2025
Primary endpoint
15 January 2026
31 January 2026

Quick facts

Lead sponsorTanta University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment80
Start date26 January 2025
Primary completion15 January 2026
Estimated completion31 January 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

18 and older, any sex, with Hepato Cellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this prospective cohort study is to evaluate the role of transient elastography (Fibroscan) in predicting the response of immunotherapy in advanced Hepatocellular carcinoma (HCC) patients. Researchers will predict the response to 6 months of HCC immunotherapy regarding improvement of the degree of liver fibrosis, development of liver decompensation, complications, survival, and mortality. Participants will undergo history-taking, clinical examination, laboratory investigations, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, Triphasic CT abdomen with contrast or MRI (for evaluation of tumor site, size and number), and Fibroscan examination at baseline and follow-up after 6 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of fibroscan

Trials testing the same drug.

Other recruiting trials for Hepato Cellular Carcinoma (HCC)

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06960863.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing